MedTrace Logo

Multicenter Observational Study of Myotonic Dystrophy Type 1

NCT02308657 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2017-10-26

No results posted yet for this study

Summary

The purpose of the study is to determine the best ways to assess how people are affected by myotonic dystrophy type 1 (DM1). The study will assess walking speed, muscle strength, muscle size, myotonia, heart rhythm, mental efficiency, and overall health. Participants will complete questionnaires to record their ideas about how they are affected by DM1. The study will evaluate people with DM1 over 1 year to determine how the condition changes over time. The study will identify biomarkers of DM1. Biomarkers are laboratory measurements that show the effects of DM1 on a person's muscle tissue or blood. Biomarkers are needed in future studies to determine how DM1 may respond to treatments.

Conditions

Sponsors & Collaborators

  • University of Florida

    collaborator OTHER

  • University of Kansas Medical Center

    collaborator OTHER

  • Ohio State University

    collaborator OTHER

  • Stanford University

    collaborator OTHER

  • National Institute of Neurological Disorders and Stroke (NINDS)

    collaborator NIH

  • Biogen

    collaborator INDUSTRY

  • Muscular Dystrophy Association

    collaborator OTHER

  • Myotonic Dystrophy Foundation

    collaborator OTHER

  • The Marigold Foundation

    collaborator UNKNOWN

  • University of Rochester

    lead OTHER

Principal Investigators

  • Charles A Thornton, MD · University of Rochester

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2017-07-31
Completion
2017-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02308657 on ClinicalTrials.gov